HINA Bioventures, a specialist investor focused on life sciences growth companies, has completed a majority growth investment in OUAT!(Brussels, Belgium) a leading provider of digital twin technology for next-generation pharmaceutical operations. OUAT!'s platform, HakoBio, enables engineering and optimization, commercial excellence, training, and asset management — supporting leading Biotech and Pharma companies, CDMOs, and technology providers worldwide.
The transaction provides new capital to accelerate growth while delivering liquidity to existing investors. OUAT!'s management team will roll over 100% of their equity. The investment in OUAT! aligns with HINA's Bioprocess 4.0 focused investment strategy, focused on investing in best-in-class providers of digital solutions for scale-up and manufacturing. The goal is to build an end-to-end digital workflow for biomanufacturing which can substantially reduce manufacturing costs & improve yields, ultimately increasing patient access to lifesaving medicines.
"HakoBio is a highly-scalable virtual lab tool, which can add huge value to customer operations and workflows. We are excited to work with the OUAT! team to further build HakoBio into an enabler of Industry 4.0 approaches, pioneering the first true integration between vendors, engineers, operators and facility managers", says Moritz von Stosch, Partner at HINA, who will join OUAT! as interim COO post-closing.
Photo: Emilie Pinard from OUAT! presenting about HakoBio at the Single-Use Event Basel, May 2026
Bron: Hinabioventures